- Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists
- Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets
NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. ( ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. These patent applications cover both standalone and combination therapies using EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment.
The newly filed patent applications support the development of EL-22, an engineered probiotic expressing myostatin, designed to revolutionize obesity care by preserving muscle mass while reducing fat mass. EL-22 has successfully completed a Phase 1 clinical trial in South Korea, demonstrating safety and tolerability in healthy volunteers. Elevai now plans to assess the efficacy of EL-22 in combination with leading weight-loss therapies to address muscle wasting—a common side effect of GLP-1 medications—while promoting fat loss.
“While GLP-1 medications such as Ozempic®, Wegovy®, and Mounjaro® dominate the obesity market, a critical gap remains in preserving lean muscle mass during weight loss,” said Deniel Mero, Co-Founder of Elevai Biosciences. “Muscle mass is vital for metabolism, strength, and overall mobility, and our patented EL-22 technology aims to address this unmet need with a first-in-class approach leveraging myostatin inhibition and oral delivery.”
The first patent application, titled “Fusion Protein of MYO-2 for Use in Treating Muscle Loss in Obese Patients” (Patent Application Serial No. 18/895,501), focuses on EL-22 as a monotherapy for treating muscle loss in obese patients. The second patent application, “Combination Therapy of a Fusion Protein of MYO-2 with a GLP-1 Receptor Agonist for Treating Muscle Loss in Obese Patients” (Patent Application Serial No. 18/895,519), covers the use of EL-22 in combination with GLP-1 receptor agonists, enhancing the benefits of current weight-loss drugs by preserving muscle mass.
These patent applications strengthen Elevai's intellectual property portfolio as the Company advances its mission to transform the standard of care for obesity treatment, with the potential to offer a differentiated therapy that preserves muscle loss, a critical component for patient health and quality of life. Elevai Biosciences’ patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets, including the USA, Japan, China and Korea.
| Licensed Product / Nation | Patent Application Serial No. | Title: |
| EL-32 USA | 18/627,462 | Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display vector operably linked with gene encoding myostatin and activin A proteins as active ingredient |
| EL-32 Korea | 10-2022-0136606 | A pharmaceutical composition for alleviation, treatment and prevention of sarcopenia containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient |
| EL-22 USA | 18/895,501 | Fusion Protein of Myo-2 for Use in Treating Muscle Loss in Obese Patients |
| EL-22 USA | 18/895,519 | Combination Therapy of a Fusion Protein of Myo-2 with a GLP-1 Receptor Agonist for Use in Treating Muscle Loss in Obese Patients |
| Patent No. | Registration No. | Title: |
| EL-22 Korea | 10-0857861-0000 | Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof |
| EL-22 Korea | 10-0872042-0000 | Cell Surface Expression Vector of Myostatin and Microorganisms Transformed Thereby |
| EL-22 USA | 8470551 | Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof |
| EL-22 Japan | 5634867 | Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof |
| EL-22 China | ZL200780101116.2 | Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof |
About Elevai Labs, Inc.
Elevai Labs Inc. ( ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Biosciences
Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in Elevai’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
